Literature DB >> 31208205

Development of a clinically relevant chemoresistant mantle cell lymphoma cell culture model.

Jia He1, Khalid A Hajj2, Christopher M Knapp2, Kathryn A Whitehead1,2.   

Abstract

Entities:  

Keywords:  CHOP; Chemoresistance; in vitro models; lymphoma

Mesh：

Substances：

Year:  2019        PMID： 31208205      PMCID： PMC6690138          DOI： 10.1177/1535370219857594

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN： 1535-3699


× No keyword cloud information.
  15 in total

1.  Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

Authors:  Jia Ruan; Peter Martin; Richard R Furman; Shing M Lee; Ken Cheung; Julie M Vose; Ann Lacasce; Julia Morrison; Rebecca Elstrom; Scott Ely; Amy Chadburn; Ethel Cesarman; Morton Coleman; John P Leonard
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

Review 2.  Cyclophosphamide toxicity. Characterising and avoiding the problem.

Authors:  L H Fraiser; S Kanekal; J P Kehrer
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 3.  Mantle cell lymphoma: evolving management strategies.

Authors:  Elias Campo; Simon Rule
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

Review 4.  Molecular pathogenesis of mantle cell lymphoma.

Authors:  Pedro Jares; Dolors Colomer; Elias Campo
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 5.  Therapies for mantle cell lymphoma: current challenges and a brighter future.

Authors:  Alan P Skarbnik; Mitchell R Smith
Journal:  Discov Med       Date:  2013-03       Impact factor: 2.970

6.  Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.

Authors:  Ekaterina Lesovaya; Alexander Yemelyanov; Kirill Kirsanov; Alexander Popa; Gennady Belitsky; Marianna Yakubovskaya; Leo I Gordon; Steven T Rosen; Irina Budunova
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

7.  Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Authors:  David Cunningham; Eliza A Hawkes; Andrew Jack; Wendi Qian; Paul Smith; Paul Mouncey; Christopher Pocock; Kirit M Ardeshna; John A Radford; Andrew McMillan; John Davies; Deborah Turner; Anton Kruger; Peter Johnson; Joanna Gambell; David Linch
Journal:  Lancet       Date:  2013-04-22       Impact factor: 79.321

Review 8.  In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma.

Authors:  Christopher M Knapp; Kathryn A Whitehead
Journal:  Expert Opin Drug Deliv       Date:  2014-09-22       Impact factor: 6.648

9.  Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.

Authors:  Stephen P Robinson; Anthony H Goldstone; Stephen Mackinnon; Angelo Carella; Nigel Russell; Carmen Ruiz de Elvira; Goli Taghipour; Norbert Schmitz
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

10.  In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.

Authors:  Martina McDermott; Alex J Eustace; Steven Busschots; Laura Breen; John Crown; Martin Clynes; Norma O'Donovan; Britta Stordal
Journal:  Front Oncol       Date:  2014-03-06       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.